The trial 's co-primary endpoints were mean changes from baseline , as area under the curve ( AUC ) , in forced expiratory volume ( FEV ( 1 ) ) over 0-12 hours ( AUC ( 0-12 h ) FEV ( 1 ) ) with MF/F versus MF , and in morning ( AM ) pre-dose ( trough ) FEV ( 1 ) with MF/F versus F after 13 weeks of treatment .
